Trends in Human Papillomavirus Vaccine Types 16 and 18 in Cervical Precancers, 2008-2014.
Adenocarcinoma in Situ
/ epidemiology
Adolescent
Adult
Female
Follow-Up Studies
Human papillomavirus 16
/ immunology
Human papillomavirus 18
/ immunology
Humans
Incidence
Papillomavirus Infections
/ complications
Papillomavirus Vaccines
/ administration & dosage
Precancerous Conditions
/ epidemiology
Prognosis
Time Factors
United States
/ epidemiology
Uterine Cervical Neoplasms
/ epidemiology
Vaccination
/ trends
Young Adult
Uterine Cervical Dysplasia
/ epidemiology
Journal
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
09
08
2018
revised:
25
10
2018
accepted:
28
11
2018
pubmed:
23
2
2019
medline:
2
5
2020
entrez:
23
2
2019
Statut:
ppublish
Résumé
The impact of human papillomavirus (HPV) vaccination has been observed in the United States through declining cervical precancer incidence in young women. To further evaluate vaccine impact, we described trends in HPV vaccine types 16/18 in cervical precancers, 2008-2014. We analyzed data from a 5-site, population-based surveillance system. Archived specimens from women age 18-39 years diagnosed with cervical intraepithelial neoplasia grades 2-3 or adenocarcinoma In 10,206 cases, the proportion and estimated number of cases of HPV16/18-positive CIN2+ declined from 52.7% (1,235 cases) in 2008 to 44.1% (819 cases) in 2014 ( From 2008-2014, the proportion of HPV16/18-positive CIN2+ declined, with the greatest declines in vaccinated women; declines in unvaccinated women suggest herd protection. The declining proportion of HPV16/18-positive CIN2+ provides additional evidence of vaccine impact in the United States.
Sections du résumé
BACKGROUND
The impact of human papillomavirus (HPV) vaccination has been observed in the United States through declining cervical precancer incidence in young women. To further evaluate vaccine impact, we described trends in HPV vaccine types 16/18 in cervical precancers, 2008-2014.
METHODS
We analyzed data from a 5-site, population-based surveillance system. Archived specimens from women age 18-39 years diagnosed with cervical intraepithelial neoplasia grades 2-3 or adenocarcinoma
RESULTS
In 10,206 cases, the proportion and estimated number of cases of HPV16/18-positive CIN2+ declined from 52.7% (1,235 cases) in 2008 to 44.1% (819 cases) in 2014 (
CONCLUSIONS
From 2008-2014, the proportion of HPV16/18-positive CIN2+ declined, with the greatest declines in vaccinated women; declines in unvaccinated women suggest herd protection.
IMPACT
The declining proportion of HPV16/18-positive CIN2+ provides additional evidence of vaccine impact in the United States.
Identifiants
pubmed: 30792242
pii: 1055-9965.EPI-18-0885
doi: 10.1158/1055-9965.EPI-18-0885
pmc: PMC6526945
mid: NIHMS1017207
doi:
Substances chimiques
Papillomavirus Vaccines
0
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
602-609Subventions
Organisme : ACL HHS
ID : U54CK000482
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000042
Pays : United States
Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States
Organisme : ACL HHS
ID : U54CK000484
Pays : United States
Organisme : NCEZID CDC HHS
ID : U54 CK000482
Pays : United States
Organisme : NCEZID CDC HHS
ID : U54 CK000484
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
©2019 American Association for Cancer Research.
Références
Clin Infect Dis. 2017 Sep 15;65(6):884-889
pubmed: 28520854
Cancer. 2015 Aug 15;121(16):2775-81
pubmed: 26098295
Pediatrics. 2012 Aug;130(2):e249-56
pubmed: 22778297
Am J Public Health. 2013 Aug;103(8):1428-35
pubmed: 23763409
PLoS One. 2012;7(3):e34044
pubmed: 22479516
J Low Genit Tract Dis. 2013 Apr;17(5 Suppl 1):S1-S27
pubmed: 23519301
Clin Infect Dis. 2019 Apr 8;68(8):1282-1291
pubmed: 30137283
Cancer Causes Control. 2014 Jul;25(7):915-22
pubmed: 24797870
JAMA Oncol. 2017 Jun 1;3(6):833-837
pubmed: 27685805
J Natl Cancer Inst. 2015 Apr 29;107(6):djv086
pubmed: 25925419
Prev Med. 2017 Oct;103:60-65
pubmed: 28765084
Natl Health Stat Report. 2011 Mar 3;(36):1-36
pubmed: 21560887
MMWR Recomm Rep. 2014 Aug 29;63(RR-05):1-30
pubmed: 25167164
J Infect Dis. 2007 Oct 15;196(8):1153-62
pubmed: 17955433
Br J Cancer. 2014 Oct 28;111(9):1824-30
pubmed: 25180766
Vaccine. 2018 Dec 18;36(52):7913-7915
pubmed: 29778520
Prev Med. 2017 Jul;100:243-247
pubmed: 28502575
Emerg Infect Dis. 2016 Jan;22(1):56-64
pubmed: 26692336
Vaccine. 2015 Mar 24;33(13):1608-13
pubmed: 25681664
Vaccine. 2018 May 31;36(23):3381-3386
pubmed: 29735321
Am J Public Health. 2016 Dec;106(12):2211-2218
pubmed: 27736208
Am J Clin Pathol. 2012 Aug;138(2):223-9
pubmed: 22904133
MMWR Surveill Summ. 2017 May 05;66(11):1-28
pubmed: 28472027
MMWR Morb Mortal Wkly Rep. 2015 Mar 27;64(11):300-4
pubmed: 25811679
J Infect Dis. 2017 Sep 1;216(5):594-603
pubmed: 28931217
J Infect Dis. 2013 Aug 1;208(3):385-93
pubmed: 23785124
Cancer Epidemiol Biomarkers Prev. 2015 Feb;24(2):393-9
pubmed: 25416715
J Epidemiol Community Health. 2017 Oct;71(10):954-960
pubmed: 28756395
MMWR Morb Mortal Wkly Rep. 2017 Aug 25;66(33):874-882
pubmed: 28837546
Am J Clin Pathol. 2012 Apr;137(4):516-42
pubmed: 22431528
J Infect Dis. 2012 Dec 15;206(12):1878-86
pubmed: 23045628
Emerg Infect Dis. 2015 Sep;21(9):1557-61
pubmed: 26291379
Lancet Infect Dis. 2014 Oct;14(10):958-66
pubmed: 25107680